8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

✍ Scribed by B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar

• Book ID: 119600779
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 68 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(09)72037-3